Core Insights - The mass spectrometry sector continues to attract capital attention despite a general cooling in investment, supported by stable development expectations from policy initiatives and the sector's high technical barriers and diverse application scenarios [2][4] Financing Overview - In 2025, there were 8 disclosed financing events in the domestic mass spectrometry sector, maintaining a similar scale to 2024. Early-stage financing (angel/A rounds) remains dominant, indicating ongoing confidence in startups with core technological potential [3][4] - Notable early-stage financing includes: - Guokexinzhi (Tianjin) Technology Development Co., Ltd. raised hundreds of thousands in April 2025 during its angel round [3] - Hefei Gravitational Wave Intelligent Spectrum Technology Co., Ltd. completed an angel round financing within a year of establishment [3] - Suzhou Aijie Boya Technology Co., Ltd. secured nearly 100 million in C round financing in February 2025, reflecting strong market validation of its technology and commercialization progress [5] - In the later financing stages, AnYipu completed nearly 100 million in B round financing, with funds directed towards enhancing core product performance and market penetration [4] Investment Activities - Major industry players like Xuedilong and United Imaging have made strategic investments in 2025, indicating ambitions for long-term industry ecosystem development [6][7] - Xuedilong established a subsidiary focused on mass spectrometry technology and invested in an innovation industrial base for analytical instruments, aligning with national strategies [7][8] Mergers and Acquisitions - Global companies such as Bruker, Waters, and Thermo Fisher have engaged in significant acquisitions, highlighting a trend where mass spectrometry is evolving into a critical component of clinical diagnostics and drug development [9][10] - Bruker acquired Biocrates and Halo Labs to enhance its capabilities in metabolomics and clinical mass spectrometry, while Waters integrated BD-related businesses to enter the clinical diagnostics space [10][11] - The acquisition of 56% of Liangxi Technology by Hexin Instruments reflects a strategy among domestic mass spectrometry firms to strengthen core technological capabilities through mergers [11]